Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for cardiac function after LAD primary PCI in non-diabetic patients
IRCT20200727048226N1Phase 2Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in myocardial infarction (MI), sponsored by Tehran University of Medical Sciences. Started Aug 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20200727048226N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200727048226N1.